De Brabander M J, Van de Veire R M, Aerts F E, Borgers M, Janssen P A
Cancer Res. 1976 Mar;36(3):905-16.
Ultrastructural investigations on mammalian cells cultured in vitro show that R 17934, a new synthetic anticancer drug, interferes with the structure and function of microtubules, both in interphase and mitotic cells. The activity of this compound in a wide range of experimental tumor systems can thus be explained partly as a direct antimitotic effect and partly as the disintegration of the normal subcellular organization of the nondividing cells. Preliminary investigations in experimental animals show that malignant cells are more susceptible to the antimicrotubular effect of R 17934 than are the nonmalignant cells of the host.
对体外培养的哺乳动物细胞进行的超微结构研究表明，一种新型合成抗癌药物R 17934，在间期细胞和有丝分裂细胞中都会干扰微管的结构和功能。因此，该化合物在多种实验性肿瘤系统中的活性，部分可解释为直接的抗有丝分裂作用，部分可解释为非分裂细胞正常亚细胞组织的解体。对实验动物的初步研究表明，恶性细胞比宿主的非恶性细胞对R 17934的抗微管作用更敏感。
